The Generic Pharmaceutical Association’s incoming CEO has an impressive resume – including helping to defeat many of GPhA's policy priorities.
Chester “Chip” Davis, whose career has been primarily focused on innovator drugs, was announced July 22 as GPhA’s new president and CEO